tradingkey.logo

Sight Sciences Inc

SGHT
View Detailed Chart
5.870USD
+0.180+3.16%
Close 02/06, 16:00ETQuotes delayed by 15 min
308.02MMarket Cap
LossP/E TTM

Sight Sciences Inc

5.870
+0.180+3.16%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.16%

5 Days

-6.53%

1 Month

-21.42%

6 Months

+59.51%

Year to Date

-25.98%

1 Year

+116.61%

View Detailed Chart

TradingKey Stock Score of Sight Sciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

Sight Sciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 102 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.35.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sight Sciences Inc's Score

Industry at a Glance

Industry Ranking
102 / 205
Overall Ranking
274 / 4521
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

Sight Sciences Inc Highlights

StrengthsRisks
Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Growing
The company is in a growing phase, with the latest annual income totaling USD 79.87M.
Undervalued
The company’s latest PE is -6.57, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 25.69M shares, decreasing 9.84% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 3.89K shares of this stock.

Analyst Rating

Based on 8 analysts
Buy
Current Rating
9.350
Target Price
+64.32%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Sight Sciences Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Sight Sciences Inc Info

Sight Sciences, Inc. is an eyecare technology company. The Company is focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The Company operates through two segments: Surgical Glaucoma and Dry Eye. The product portfolio for the Surgical Glaucoma segment features the OMNI Surgical System, which is an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, and the SION Surgical Instrument is a bladeless, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The product portfolio for the Dry Eye segment consists of the TearCare System (TearCare) for ophthalmologists and optometrists. TearCare is used by adult patients with evaporative dry eye disease due to meibomian gland disease (MGD), enabling clearance of gland obstructions by physicians to address the cause of dry eye disease.
Ticker SymbolSGHT
CompanySight Sciences Inc
CEOBadawi (Paul)
Websitehttps://www.sightsciences.com/
KeyAI